Benign prostatic hyperplasia (BPH) is a benign growth of the prostate gland that can make it difficult to urinate and cause symptoms such as decreased force of the urinary stream, difficulty starting urination, increased urinary frequency, or the need to get up to urinate at night.

Many patients begin treatment with oral medication. However, in some cases, this does not provide sufficient symptom relief or may cause side effects such as dizziness, fatigue, or sexual dysfunction. In these situations, UroLift may be a therapeutic alternative.

The ^UroLift® system is a minimally invasive treatment that uses small, permanent implants to separate the prostatic tissue compressing the urethra, without the need for prostate removal. This widens the urinary tract, improving urine flow and relieving the symptoms of benign prostatic hyperplasia (BPH).

The procedure involves inserting the device through the urethra, where the implants are individually placed to keep the prostatic lobes open and reduce urinary obstruction. Because it is a minimally invasive technique, it is usually performed on an outpatient basis under local anesthesia or sedation, allowing for same-day discharge and, in most cases, without the need for a urinary catheter. Furthermore, it is a safe and effective treatment that preserves erectile and ejaculatory function.

UroLift is indicated for selected patients with benign prostatic hyperplasia (BPH) , especially those with mild to moderate symptoms and prostates up to 80 cc , who wish to avoid prolonged drug treatment or experience medication-related side effects. The indication should always be assessed individually by a urologist experienced in this technique.